Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study
Richard Furie(Hofstra University), Victoria P. Werth(Philadelphia VA Medical Center), Allison Gaudy(University of Rochester Medical Center), Nikolay Delev(Bristol-Myers Squibb (Sweden)), Xiaojiang Zhan(Nanchang University), Shimon Korish(Bristol-Myers Squibb (United States)), Ying Ye(Dalian Medical University), Douglas R. Hough(Bristol-Myers Squibb (United States)), Peter Schäfer(Bristol-Myers Squibb (United States)), Michael Weiswasser(Bristol-Myers Squibb (United States))
Cited by 37
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
The immune cell landscape in kidneys of patients with lupus nephritis
|Nature Immunology|2019|840
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
|Journal of the American Academy of Dermatology|2008|597
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
|The Lancet Rheumatology|2019|478